文献速递胸部肿瘤

呼出气冷凝液检测肺癌患者EGFR T790M突变简报

Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients.
PubMed 文献 · J Thorac Oncol · 2018-05-08

EGFR T790M是非小细胞肺癌对酪氨酸激酶抑制剂最常见的耐药机制,晚期患者不一定能重复活检。血浆检测T790M灵敏度低限制其临床应用,呼出气冷凝液是易采集的样本且已知含游离DNA包括肺癌突变。本简报详述呼出气冷凝液检测EGFR T790M突变的潜在效用。

要点

  • EGFR T790M是非小细胞肺癌对酪氨酸激酶抑制剂最常见的耐药机制。
  • 晚期患者不一定能重复活检,血浆检测T790M灵敏度低限制临床应用。
  • 呼出气冷凝液易采集且含游离DNA,可能用于检测T790M突变。

核心结论

  • 呼出气冷凝液在检测EGFR T790M突变方面具有潜在效用。

研究设计与样本

  • 本报告为简报,详述呼出气冷凝液检测EGFR T790M突变的潜在效用。

主要发现

  • 呼出气冷凝液是易采集的样本,已知含游离DNA包括肺癌突变。

临床怎么用

  • 呼出气冷凝液作为非侵入性方法,可能用于无法重复活检患者检测T790M。

局限性

  • 血浆检测T790M灵敏度低限制其临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The EGFR T790M somatic mutation is the most common mechanism of resistance to tyrosine kinase inhibitors in NSCLC. Patients with advanced disease are not always amenable to repeat biopsy for further molecular analysis. Developing noninvasive methods to detect T790M in cell-free DNA in the absence of tissue is being actively investigated. Unfortunately, the low sensitivity of plasma for detection of T790M has limited its clinical use. Exhaled breath condensate (EBC) is an easily collected sample that is known to harbor cell-free DNA, including lung cancer mutations. This report details the potential utility of exhaled breath condensate in the detection of the EGFR T790M mutation.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Smyth RJ, Toomey SM, Sartori A, et al. Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients. J Thorac Oncol. 2018. PMID: 29751135. doi:10.1016/j.jtho.2018.04.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。